Department of Health and Human Services February 7, 2022 – Federal Register Recent Federal Regulation Documents
Results 1 - 9 of 9
Submission for OMB Review; ORR-6 Performance Report (OMB #0970-0036)
The Administration for Children and Families (ACF), Office of Refugee Resettlement (ORR) is requesting an extension of the ORR-6 Performance Report (OMB #0970-0036, expiration 2/28/2022) until 8/31/ 2022. ORR published a notice in the Federal Register on 8/12/2021 requesting comments within 60-days on revisions to the ORR-6. A related revision request will be submitted to the Office of Management and Budget along with an additional 30-day comment period prior to 8/12/ 2022.
Agency Information Collection Activities; Proposed Collection; Comment Request; Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke Under the Federal Food, Drug, and Cosmetic Act
The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke Under the Federal Food, Drug, and Cosmetic Act.
Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Environmental Impact Considerations
The Food and Drug Administration (FDA, Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Notifying the Food and Drug Administration of a Permanent Discontinuance or Interruption in Manufacturing of a Device Under Section 506J of the Federal Food, Drug, and Cosmetic Act; Draft Guidance for Industry and Food and Drug Administration Staff; Availability; Extension of Comment Period
The Food and Drug Administration (FDA or the Agency) is extending the comment period for the notice of availability that appeared in the Federal Register of January 11, 2022. In the notice of availability, FDA requested comments on draft guidance for industry and FDA staff entitled ``Notifying the Food and Drug Administration of a Permanent Discontinuance or Interruption in Manufacturing of a Device Under Section 506J of the Federal Food, Drug, and Cosmetic Act.'' The Agency is taking this action in response to a request for an extension to allow interested persons additional time to submit comments.
Government-Owned Inventions; Availability for Licensing
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Formal Meetings Between the Food and Drug Administration and Sponsors or Requestors of Over-the-Counter Monograph Drugs; Draft Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled ``Formal Meetings Between FDA and Sponsors or Requestors of Over-the-Counter Monograph Drugs.'' This draft guidance provides recommendations to industry on formal meetings between FDA and sponsors or requestors of over-the-counter (OTC) monograph drugs.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
